Development of chimaeric West Nile virus attenuated vaccine candidate based on the Japanese encephalitis vaccine strain SA14-14-2

Journal of General Virology

Volumn 94, Issue PART 12, 2013, Pages 2700-2709

  Li, Xiao Feng ^a   Zhao, Wei ^b   Lin, Fang ^c   Ye, Qing ^a   Wang, Hong Jiang ^a   Yang, Dong ^a,d   Li, Shi Hua ^a   Zhao, Hui ^a   Xu, Yan Peng ^a   Ma, Jie ^a   Deng, Yong Qiang ^a   Zhang, Yu ^a   Qin, E De ^a   Qin, Cheng Feng ^a,e,f  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

^d XINJIANG AGRICULTURAL UNIVERSITY   (China)

^e ANHUI MEDICAL UNIVERSITY   (China)

^f GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

JAPANESE ENCEPHALITIS VACCINE; LIVE VACCINE; WEST NILE VACCINE;

ADAPTIVE IMMUNITY; ANIMAL CELL; ARTICLE; BLOOD; BRAIN; CONTROLLED STUDY; GENETIC STABILITY; IMMUNOGENICITY; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS REPLICATION; WEST NILE FLAVIVIRUS;

ANIMALS; BRAIN; CELL LINE; DRUG DESIGN; ENCEPHALITIS VIRUS, JAPANESE; FEMALE; HUMANS; JAPANESE ENCEPHALITIS VACCINES; MICE; MICE, INBRED BALB C; RECOMBINANT PROTEINS; VACCINES, ATTENUATED; VIRAL ENVELOPE PROTEINS; VIRULENCE; VIRUS REPLICATION; WEST NILE FEVER; WEST NILE VIRUS; WEST NILE VIRUS VACCINES;

EID: 84887529093     PISSN: 00221317     EISSN: 14652099     Source Type: Journal    
DOI: 10.1099/vir.0.059436-0     Document Type: Article

References (48)

1. Alonso-Padilla, J., Jimé nez de Oya, N., Blá zquez, A. B., Escribano-Romero, E., Escribano, J. M. & Saiz, J. C. (2011). Recombinant West Nile virus envelope protein E and domain III expressed in insect larvae protects mice against West Nile disease. Vaccine 29, 1830-1835.
2. Arroyo, J., Miller, C. A., Catalan, J. & Monath, T. P. (2001). Yellow fever vector live-virus vaccines: West Nile virus vaccine development. Trends Mol Med 7, 350-354.
3. Arroyo, J., Miller, C., Catalan, J., Myers, G. A., Ratterree, M. S., Trent, D. W. & Monath, T. P. (2004). ChimeriVax-West Nile virus liveattenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy. J Virol 78, 12497-12507.
4. Biedenbender, R., Bevilacqua, J., Gregg, A. M., Watson, M. & Dayan, G. (2011). Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults. J Infect Dis 203, 75-84.
5. Bista, M. B., Banerjee, M. K., Shin, S. H., Tandan, J. B., Kim, M. H., Sohn, Y. M., Ohrr, H. C., Tang, J. L. & Halstead, S. B. (2001). Efficacy of single-dose SA 14-14-2 vaccine against Japanese encephalitis: a case control study. Lancet 358, 791-795.
6. Bray, M. & Lai, C. J. (1991). Construction of intertypic chimeric dengue viruses by substitution of structural protein genes. Proc Natl Acad Sci U S A 88, 10342-10346.
7. Centers for Disease Control and Prevention (CDC) (2012). West Nile virus disease and other arboviral diseases-United States, 2011. MMWR Morb Mortal Wkly Rep 61, 510-514.
8. Chambers, T. J., Nestorowicz, A., Mason, P. W. & Rice, C. M. (1999). Yellow fever/Japanese encephalitis chimeric viruses: construction and biological properties. J Virol 73, 3095-3101.
9. Chang, D. C., Liu, W. J., Anraku, I., Clark, D. C., Pollitt, C. C., Suhrbier, A., Hall, R. A. & Khromykh, A. A. (2008). Single-round infectious particles enhance immunogenicity of a DNA vaccine against West Nile virus. Nat Biotechnol 26, 571-577.
10. Coutant, F., Frenkiel, M. P., Despres, P. & Charneau, P. (2008). Protective antiviral immunity conferred by a nonintegrative lentiviral vector-based vaccine. PLoS ONE 3, e3973.
11. Davis, B. S., Chang, G. J., Cropp, B., Roehrig, J. T., Martin, D. A., Mitchell, C. J., Bowen, R. & Bunning, M. L. (2001). West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays. J Virol 75, 4040-4047.
12. Deng, Y. Q., Dai, J. X., Ji, G. H., Jiang, T., Wang, H. J., Yang, H. O., Tan, W. L., Liu, R., Yu, M. & other authors (2011). A broadly flavivirus cross-neutralizing monoclonal antibody that recognizes a novel epitope within the fusion loop of E protein. PLoS ONE 6, e16059.
13. Desprè s, P., Combredet, C., Frenkiel, M. P., Lorin, C., Brahic, M. & Tangy, F. (2005). Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis. J Infect Dis 191, 207-214.
14. Durbin, A. P., Karron, R. A., Sun, W., Vaughn, D. W., Reynolds, M. J., Perreault, J. R., Thumar, B., Men, R., Lai, C. J. & other authors (2001). Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 39-untranslated region. Am J Trop Med Hyg 65, 405-413.
15. Gatchalian, S., Yao, Y., Zhou, B., Zhang, L., Yoksan, S., Kelly, K., Neuzil, K. M., Yaïch, M. & Jacobson, J. (2008). Comparison of the immunogenicity and safety of measles vaccine administered alone or with live, attenuated Japanese encephalitis SA 14-14-2 vaccine in Philippine infants. Vaccine 26, 2234-2241.
16. Guirakhoo, F., Zhang, Z. X., Chambers, T. J., Delagrave, S., Arroyo, J., Barrett, A. D. & Monath, T. P. (1999). Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis. Virology 257, 363-372.
17. Guirakhoo, F., Weltzin, R., Chambers, T. J., Zhang, Z. X., Soike, K., Ratterree, M., Arroyo, J., Georgakopoulos, K., Catalan, J. & Monath, T. P. (2000). Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J Virol 74, 5477-5485.
18. Hennessy, S., Liu, Z., Tsai, T. F., Strom, B. L., Wan, C. M., Liu, H. L., Wu, T. X., Yu, H. J., Liu, Q. M. & other authors (1996). Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): a case-control study. Lancet 347, 1583-1586.
19. Huang, C. Y., Butrapet, S., Pierro, D. J., Chang, G. J., Hunt, A. R., Bhamarapravati, N., Gubler, D. J. & Kinney, R. M. (2000). Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine. J Virol 74, 3020-3028.
20. Iyer, A. V., Pahar, B., Boudreaux, M. J., Wakamatsu, N., Roy, A. F., Chouljenko, V. N., Baghian, A., Apetrei, C., Marx, P. A. & Kousoulas, K. G. (2009). Recombinant vesicular stomatitis virus-based west Nile vaccine elicits strong humoral and cellular immune responses and protects mice against lethal challenge with the virulent West Nile virus strain LSU-AR01. Vaccine 27, 893-903.
21. Kahler, S. C. (2003). APHIS: West Nile virus vaccine safe for use. J Am Vet Med Assoc 223, 416-418.
22. Kumar, R., Tripathi, P. & Rizvi, A. (2009). Effectiveness of one dose of SA 14-14-2 vaccine against Japanese encephalitis. N Engl J Med 360, 1465-1466.
23. Ledgerwood, J. E., Pierson, T. C., Hubka, S. A., Desai, N., Rucker, S., Gordon, I. J., Enama, M. E., Nelson, S., Nason, M. & other authors (2011). A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial. J Infect Dis 203, 1396-1404.
24. Lee, E., Stocks, C. E., Amberg, S. M., Rice, C. M. & Lobigs, M. (2000). Mutagenesis of the signal sequence of yellow fever virus prM protein: enhancement of signalase cleavage in vitro is lethal for virus production. J Virol 74, 24-32.
25. Li, X. F., Jiang, T., Yu, X. D., Deng, Y. Q., Zhao, H., Zhu, Q. Y., Qin, E. D. & Qin, C. F. (2010). RNA elements within the 59 untranslated region of the West Nile virus genome are critical for RNA synthesis and virus replication. J Gen Virol 91, 1218-1223.
26. Lieberman, M. M., Nerurkar, V. R., Luo, H., Cropp, B., Carrion, R., Jr, de la Garza, M., Coller, B. A., Clements, D., Ogata, S. & other authors (2009). Immunogenicity and protective efficacy of a recombinant subunit West Nile virus vaccine in rhesus monkeys. Clin Vaccine Immunol 16, 1332-1337.
27. Lim, C. K., Takasaki, T., Kotaki, A. & Kurane, I. (2008). Vero cellderived inactivated West Nile (WN) vaccine induces protective immunity against lethal WN virus infection in mice and shows a facilitated neutralizing antibody response in mice previously immunized with Japanese encephalitis vaccine. Virology 374, 60-70.
28. Martina, B. E., van den Doel, P., Koraka, P., van Amerongen, G., Spohn, G., Haagmans, B. L., Provacia, L. B., Osterhaus, A. D. & Rimmelzwaan, G. F. (2011). A recombinant influenza A virus expressing domain III of West Nile virus induces protective immune responses against influenza and West Nile virus. PLoS ONE 6, e18995.
29. Minke, J. M., Siger, L., Karaca, K., Austgen, L., Gordy, P., Bowen, R., Renshaw, R. W., Loosmore, S., Audonnet, J. C. & Nordgren, B. (2004). Recombinant canarypoxvirus vaccine carrying the prM/E genes of West Nile virus protects horses against a West Nile virusmosquito challenge. Arch Virol Suppl. 221-230.
30. Monath, T. P., Guirakhoo, F., Nichols, R., Yoksan, S., Schrader, R., Murphy, C., Blum, P., Woodward, S., McCarthy, K. & other authors (2003). Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J Infect Dis 188, 1213-1230.
31. Nelson, M. H., Winkelmann, E., Ma, Y., Xia, J., Mason, P. W., Bourne, N. & Milligan, G. N. (2010). Immunogenicity of RepliVAX WN, a novel single-cycle West Nile virus vaccine. Vaccine 29, 174-182.
32. Ng, T., Hathaway, D., Jennings, N., Champ, D., Chiang, Y. W. & Chu, H. J. (2003). Equine vaccine for West Nile virus. Dev Biol (Basel) 114, 221-227.
33. Petersen, L. R., Carson, P. J., Biggerstaff, B. J., Custer, B., Borchardt, S. M. & Busch, M. P. (2012). Estimated cumulative incidence of West Nile virus infection in US adults, 1999-2010. Epidemiol Infect 28, 1-5.
34. Pizzi, M. (1950). Sampling variation of the fifty percent end-point, determined by the Reed-Muench (Behrens) method. Hum Biol 22, 151-190.
35. Pletnev, A. G., Bray, M., Huggins, J. & Lai, C. J. (1992). Construction and characterization of chimeric tick-borne encephalitis/dengue type 4 viruses. Proc Natl Acad Sci U S A 89, 10532-10536.
36. Pletnev, A. G., Bray, M., Hanley, K. A., Speicher, J. & Elkins, R. (2001). Tick-borne Langat/mosquito-borne dengue flavivirus chimera, a candidate live attenuated vaccine for protection against disease caused by members of the tick-borne encephalitis virus complex: evaluation in rhesus monkeys and in mosquitoes. J Virol 75, 8259-8267.
37. Pletnev, A. G., Putnak, R., Speicher, J., Wagar, E. J. & Vaughn, D. W. (2002). West Nile virus/dengue type 4 virus chimeras that are reduced in neurovirulence and peripheral virulence without loss of immunogenicity or protective efficacy. Proc Natl Acad Sci U S A 99, 3036-3041.
38. Pletnev, A. G., Claire, M. S., Elkins, R., Speicher, J., Murphy, B. R. & Chanock, R. M. (2003). Molecularly engineered live-attenuated chimeric West Nile/dengue virus vaccines protect rhesus monkeys from West Nile virus. Virology 314, 190-195.
39. Pletnev, A. G., Swayne, D. E., Speicher, J., Rumyantsev, A. A. & Murphy, B. R. (2006). Chimeric West Nile/dengue virus vaccine candidate: preclinical evaluation in mice, geese and monkeys for safety and immunogenicity. Vaccine 24, 6392-6404.
40. Posadas-Herrera, G., Inoue, S., Fuke, I., Muraki, Y., Mapua, C. A., Khan, A. H., Parquet, M. del. C., Manabe, S., Tanishita, O. & other authors (2010). Development and evaluation of a formalininactivated West Nile Virus vaccine (WN-VAX) for a human vaccine candidate. Vaccine 28, 7939-7946.
41. Prow, T. W., Chen, X., Prow, N. A., Fernando, G. J., Tan, C. S., Raphael, A. P., Chang, D., Ruutu, M. P., Jenkins, D. W. & other authors (2010). Nanopatch-targeted skin vaccination against West Nile Virus and Chikungunya virus in mice. Small 6, 1776-1784.
42. Samina, I., Khinich, Y., Simanov, M. & Malkinson, M. (2005). An inactivated West Nile virus vaccine for domestic geese-efficacy study and a summary of 4 years of field application. Vaccine 23, 4955-4958.
43. Schepp-Berglind, J., Luo, M., Wang, D., Wicker, J. A., Raja, N. U., Hoel, B. D., Holman, D. H., Barrett, A. D. & Dong, J. Y. (2007). Complex adenovirus-mediated expression of West Nile virus C, PreM, E, and NS1 proteins induces both humoral and cellular immune responses. Clin Vaccine Immunol 14, 1117-1126.
44. Tandan, J. B., Ohrr, H., Sohn, Y. M., Yoksan, S., Ji, M., Nam, C. M. & Halstead, S. B. (2007). Single dose of SA 14-14-2 vaccine provides longterm protection against Japanese encephalitis: a case-control study in Nepalese children 5 years after immunization. Vaccine 25, 5041-5045.
45. Uhrlaub, J. L., Brien, J. D., Widman, D. G., Mason, P. W. & Nikolich-Zugich, J. (2011). Repeated in vivo stimulation of T and B cell responses in old mice generates protective immunity against lethal West Nile virus encephalitis. J Immunol 186, 3882-3891.
46. Widman, D. G., Ishikawa, T., Winkelmann, E. R., Infante, E., Bourne, N. & Mason, P. W. (2009). RepliVAX WN, a single-cycle flavivirus vaccine to prevent West Nile disease, elicits durable protective immunity in hamsters. Vaccine 27, 5550-5553.
47. Ye, Q., Li, X. F., Zhao, H., Li, S. H., Deng, Y. Q., Cao, R. Y., Song, K. Y., Wang, H. J., Hua, R. H. & other authors (2012). A single nucleotide mutation in NS2A of Japanese encephalitis-live vaccine virus (SA14-14-2) ablates NS19 formation and contributes to attenuation. J Gen Virol 93, 1959-1964.
48. Yu, Y. (2010). Phenotypic and genotypic characteristics of Japanese encephalitis attenuated live vaccine virus SA14-14-2 and their stabilities. Vaccine 28, 3635-3641.